The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03304288 |
Recruitment Status :
Active, not recruiting
First Posted : October 9, 2017
Last Update Posted : January 20, 2021
|
Sponsor:
Peking University People's Hospital
Collaborators:
Beijing Hospital
Navy General Hospital, Beijing
Beijing Tongren Hospital
Information provided by (Responsible Party):
Xiao-hui Zhang, Peking University People's Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Actual Primary Completion Date : | January 15, 2021 |
Estimated Study Completion Date : | February 28, 2021 |